Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Use of Antiemetic Agents in Acute Gastroenteritis 3. 2008 Exclusive Survey—Earnings: Good news for primary care income 4. Medicare pay-for-reporting effort draws fire from frustrated doctors 5. Debunking Myths in the US Healthcare System
Your Article Summary
The Novel CXCR4 Antagonist KRH-3955 Is an Orally Bioavailable and Extremely Potent Inhibitor of Human Immunodeficiency Virus Type 1 Infection: Comparative Studies with AMD3100
Antimicrobial Agents and Chemotherapy, 07/01/09
Murakami T et al. - The compound shows an oral bioavailability of 25.6% in rats, and its oral administration blocks X4 HIV-1 replication in the human peripheral blood lymphocyte-severe combined immunodeficiency mouse system. Thus, KRH-3955 is a new promising agent for HIV-1 infection and AIDS.
Today in Basic Science/Genetics...keeping you current
Receive free subspecialty "5-minute updates" via email
Innate immune responses to influenza A H5N1: friend or foe
Trends in Immunology, 10/30/09
Actinobacteria as mutualists: general healthcare for insects
Trends in Microbiology, 11/04/09
Age dependency and Pseudomonas aeruginosa genotype prevalence in Dutch cystic fibrosis patients
Journal of Clinical Microbiology, 11/02/09
Today in HIV/Immunodeficiency...keeping you current
Receive free subspecialty "5-minute updates" via email
Effectiveness of Increasing Emergency Department Patients' Self-perceived Risk for Being Human Immunodeficiency Virus (HIV) Infected Through Audio Computer Self-interview–based Feedback About Reported HIV Risk Behaviors
Academic Emergency Medicine, 11/11/09
HIV-Specific Health Care Utilization and Mortality among Tuberculosis/HIV Coinfected Persons
AIDS Patient Care and STDs, 10/06/09
Acyclovir: a new use for an old drug
Current Opinion in Infectious Diseases, 10/28/09
Article Search
Sponsor


See Latest Articles


